During the early stages of tumor development, disease progression is controlled by the T-cell response against tumor-derived antigens, characterized by release of Th-1 cytokines, NK cells recruitment and the presence of CD8+ cytotoxic T cells (CTLs), which identify and kill the more immunogenic cancer cells (i.e., cancer immunosurveillance) [45]. Here, CD8A is linked to neoplasm.